Analysts Are Upgrading Artemis Medicare Services Limited (NSE:ARTEMISMED) After Its Latest Results

It's been a good week for Artemis Medicare Services Limited (NSE:ARTEMISMED) shareholders, because the company has just released its latest second-quarter results, and the shares gained 9.8% to ₹269. Artemis Medicare Services reported in line with analyst predictions, delivering revenues of ₹2.7b and statutory earnings per share of ₹5.31, suggesting the business is executing well and in line with its plan. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the four analysts covering Artemis Medicare Services are now predicting revenues of ₹11.2b in 2026. If met, this would reflect a solid 12% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to increase 10.0% to ₹7.50. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹10.7b and earnings per share (EPS) of ₹7.00 in 2026. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.

See our latest analysis for Artemis Medicare Services

With these upgrades, we're not surprised to see that the analysts have lifted their price target 10% to ₹308per share. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Artemis Medicare Services analyst has a price target of ₹370 per share, while the most pessimistic values it at ₹266. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Artemis Medicare Services shareholders.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Artemis Medicare Services' growth to accelerate, with the forecast 25% annualised growth to the end of 2026 ranking favourably alongside historical growth of 18% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 19% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Artemis Medicare Services to grow faster than the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Artemis Medicare Services' earnings potential next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Artemis Medicare Services going out to 2028, and you can see them free on our platform here..

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.